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ABSTRACT
A 2-month prospective study of Clostridium difﬁcile infections was conducted in 38 hospitals from 14
different European countries in order to obtain an overview of the phenotypic and genotypic features of
clinical isolates of C. difﬁcile during 2005. Of 411 isolates from diarrhoeagenic patients with suspected
C. difﬁcile-associated diarrhoea (CDAD), 354 were toxigenic, of which 86 (24.3%) were toxin-variant
strains. Major toxinotypes included toxinotypes 0 (n = 268), V (n = 28), VIII (n = 22) and III (n = 25).
MICs of metronidazole, vancomycin, erythromycin, clindamycin, moxiﬂoxacin and tetracycline were
determined using the Etest method. All the toxigenic strains were fully-susceptible to metronidazole and
vancomycin. Resistance to erythromycin, clindamycin, tetracycline and moxiﬂoxacin was found in
44.4%, 46.1%, 9.2% and 37.5% of the isolates, respectively. Sixty-six different PCR ribotypes were
characterised, with the 027 epidemic strain accounting for 6.2% of isolates. This strain was positive for
binary toxin genes, had an 18-bp deletion in the tcdC gene, and was resistant to both erythromycin and
moxiﬂoxacin. The mean incidence of CDAD was 2.45 cases ⁄ 10 000 patient-days, but this ﬁgure varied
widely among the participating hospitals. Patients infected with the 027 strain were more likely to have
a severe disease (OR 3.29, 95% CI 1.19–9.16, p 0.008) and to have been speciﬁcally treated with
metronidazole or vancomycin (OR 7.46, 95% CI 1.02–154, p 0.02). Ongoing epidemiological surveillance
of cases of CDAD, with periodic characterisation of the strains involved, is required to detect clustering
of cases in time and space and to monitor the emergence of speciﬁc highly virulent clones.
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INTRODUCTION
Since the recognition of Clostridium difﬁcile as the
main cause of pseudomembranous colitis in 1978,
this anaerobic spore-forming bacterium has
emerged as an important enteropathogen [1,2].
C. difﬁcile is currently responsible for virtually all
cases of pseudomembranous colitis and for
10–25% of cases of antibiotic-associated diarrhoea
[3]. C. difﬁcile is also the leading cause of nosoco-
mial diarrhoea among adults in industrialised
countries [4], and many hospital outbreaks of
infection have been described worldwide [5–7].
The primary virulence factors of C. difﬁcile are
the two large clostridial toxins, toxin A (TcdA)
and toxin B (TcdB). TcdA and TcdB both disrupt
the actin cytoskeleton of intestinal epithelial
cells by means of UDP-glucose-dependent glu-
cosylation of proteins from the Rho and Ras
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sub-families [8]. A third toxin, named binary
toxin (actin-speciﬁc ADP-ribosyltransferase), was
described in C. difﬁcile strain CD196 in 1988 [9].
Binary toxin is coded by two genes (cdtA and
cdtB), which have been cloned and sequenced
[10], and has a prevalence in human isolates of
C. difﬁcile of 1.6–20.8% [11–14]. However, the
clinical relevance and pathogenic role of the
binary toxin in C. difﬁcile-associated human infec-
tions remain unknown.
Since 2003, increasing numbers of cases of
C. difﬁcile-associated diarrhoea (CDAD) with a
more severe course have been reported in Canada
and the USA [15–18]. This trend has been asso-
ciated with the rapid emergence and spread of a
speciﬁc clone of C. difﬁcile belonging to PCR
ribotype 027 or pulsotype NAP1 (North American
Pulsotype 1) [19]. The increased virulence of this
clone might be associated with overproduction of
toxins A and B, and ⁄ or with the production of the
binary toxin [19]. This epidemic clone is also
characterised by its resistance to erythromycin
and to the newer ﬂuoroquinolones (i.e., moxiﬂox-
acin, gatiﬂoxacin and levoﬂoxacin) [20]. First
detected in North America, C. difﬁcile 027 has
spread rapidly and has also been responsible for
outbreaks in various countries in Europe, includ-
ing the UK, Belgium, The Netherlands and France
[21–23]. Dissemination of this strain throughout
Europe could lead to important changes in the
epidemiology of CDAD. There is therefore a need
for ongoing clinical and molecular surveillance of
CDAD.
The aims of the present study were: (i) to
obtain an overview of the phenotypic (toxigenic-
ity, antimicrobial susceptibility) and genotypic
(toxinotypes, PCR ribotypes, genes for binary
toxin) features of C. difﬁcile isolates from
different European countries during 2005; (ii)
to determine the point prevalence of the
epidemic clone 027; and (iii) to estimate the
incidence of CDAD among hospitalised patients
in Europe.
MATERIALS AND METHODS
Study organisation
This prospective study was conducted during a 2-month
period (April–June 2005) in 38 hospitals in 14 different
European countries, namely Belgium, France, Germany, Hun-
gary, the UK, Italy, The Netherlands, Poland, Spain, Switzer-
land, Sweden, Turkey, Greece and Ireland. Participation in this
study was on a voluntary basis; however, participating
hospitals were required to have an on-site microbiology
laboratory, to systematically perform culture whenever a test
for C. difﬁcile was requested, and to complete a clinical
questionnaire for each C. difﬁcile isolate (regardless of the
toxin result). In each country, a local coordinator was respon-
sible for recruiting three hospitals, for collecting the isolates
and the clinical data, and for forwarding them to the central
coordinator (FB).
Isolates and patients
All C. difﬁcile isolates from inpatients were included in the
study; isolates from outpatients, day-care patients or children
aged <2 years were excluded. Repetitive isolates from the
same patient were excluded unless a recurrent case of CDAD
was involved. A standardised questionnaire was completed
for each patient, including administrative data (age, gender,
ward, previous hospitalisation), clinical data concerning the
severity of the disease (fever, abdominal pain, ileus, toxic
megacolon, perforation), biological parameters (albuminaemia,
polynuclear neutrophil (PNN) count), risk-factors in the month
preceding the onset of diarrhoea (antimicrobial treatment,
chemotherapy, nasogastric intubation, abdominal surgery),
endoscopic examination and treatment.
Deﬁnitions
Diarrhoea was deﬁned as two or more loose stools ⁄day for at
least 2 days. A case of CDAD was deﬁned as a diarrhoeagenic
patient with a positive toxigenic C. difﬁcile culture. A case of
CDADwas classiﬁed as severe if the patient fulﬁlled at least one
of the following three criteria: (i) PNN count ‡20 000 ⁄mm3; (ii)
complications, e.g., death with C. difﬁcile as the primary or
contributory cause, toxic megacolon or perforation; or (iii)
colectomy performed as surgical management of CDAD.
CDAD was considered to be community-acquired if the
diarrhoea occurred within 72 h of admission and if the patient
had no history of hospitalisation during the previous month.
Otherwise, CDAD was deﬁned as healthcare-associated.
Recurrences were deﬁned as patients with a reappearance of
symptoms at least 10 days after the onset of the ﬁrst episode and
within the following 3 months, and a positive toxigenic culture.
Two episodes of CDAD in the same patient were considered to
be distinct events if they occurred >3 months apart.
Statistical analysis
Administrative data (total no. of admissions, total no. of
patient-days) related to the study period were requested for
each hospital. Data were entered into EpiInfo software v.6.04
(CDC, Atlanta, GA, USA). Chi-square tests or Fisher’s exact
tests (for qualitative variables) and the ANOVA test (for
quantitative variables) were used to evaluate differences
among patient subgroups, with p <0.05 considered to be
statistically signiﬁcant.
Culture
Culture and identiﬁcation of C. difﬁcilewere performed in each
participating laboratory according to standard local tech-
niques. Isolates sent to the central coordinating laboratory
were subcultured on selective medium (brain–heart infusion
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agar supplemented with deﬁbrinated horse blood 5% v ⁄v,
sodium taurocholate 0.1% w ⁄v, cefoxitin 10 mg ⁄L and cyclo-
serine 250 mg ⁄L) in an anaerobic atmosphere at 37C for 48 h.
If colonies did not have the expected features (i.e., Gram-
positive cells, characteristic odour, typical morphological
features), identiﬁcation was conﬁrmed using the API 32 A
system (bioMe´rieux, La Balme-les Grottes, France). Isolates
were stored at )80C in 1 mL of brain–heart infusion broth
containing glycerol 10% v ⁄v.
Detection of toxins A and B
Two-to-four colonies were inoculated in brain–heart infusion
broth and incubated for 4 days under anaerobic conditions.
The supernatant from this culture was ﬁltered and inoculated
on Vero cells to determine cytotoxicity as described previously
[24]. Toxin A was detected using the C. difﬁcile toxin A test
(Oxoid, Basingstoke, UK) and a suspension of ten colonies
resuspended in phosphate-buffered saline according to the
manufacturer’s recommendations.
MIC determination
C. difﬁcile cultures grown in Brucella broth for 24 hwere diluted
to a 1 · McFarland standard and rapidly swabbed in three
directions on pre-reduced Brucella blood agar plates supple-
mented with haemin 5 mg ⁄L and vitamin K1 1 mg ⁄L. Etest
strips containing vancomycin, metronidazole, erythromycin,
clindamycin, moxiﬂoxacin or tetracycline (AB Biodisk, Solna,
Sweden) were applied to the agar surface and the plates were
incubated in an anaerobic atmosphere. MICs were read at the
point where the elliptical zone of inhibition intersected the MIC
scale after incubation for 24 h (except for clindamycin, which
required incubation for 48 h). Resistancewas deﬁned according
to the following breakpoints: vancomycin ‡ 32 mg ⁄L, metroni-
dazole ‡ 32 mg ⁄L, erythromycin ‡ 4 mg ⁄L, clindamycin
‡ 4 mg ⁄L, moxiﬂoxacin ‡ 4 mg ⁄L, and tetracycline ‡ 8 mg ⁄L.
Quality control strains used for susceptibility testing included
Bacteroides thetaiotaomicronATCC 29741. Five C. difﬁcile isolates
were not available for MIC determinations.
Detection of the cdtA and cdtB genes
PCRs to detect the cdtA and cdtB genes were performed as
described previously [25]. DNA was extracted with the
Instagene Matrix kit (Bio-Rad, Ivry, France). PCRs were
performed in a ﬁnal volume of 50 lL containing 50 mM KCl,
10 mM Tris-HCl, pH 9.0, Triton X-100 1% v ⁄v, 1.5 mM
MgCl2, 200 lM each dNTP, 0.15 lM each primer, 1 U of
Taq polymerase and 5 lL of template DNA. Ampliﬁcation
comprised 30 cycles of 94C for 45 s, 52C for 1 min and
75C for 1 min 20 s. Strain CD196 was used as a positive
control and strain ATCC 43598 (serogroup F) was used as a
negative control [9].
Toxinotyping
Toxinotyping is based on PCR-restriction analysis of a
19-kb region encompassing the C. difﬁcile pathogenicity
locus (PaLoc). The oligonucleotide primers used were
those described by Rupnik et al. [26]. The ﬁrst 3.1 kb of
tcdB (PCR fragment B1) and a 3.1-kb fragment spanning the
repetitive region of tcdA (PCR fragment A3), obtained with
primer sets A3C ⁄A4N and B1C ⁄B2N, respectively, were
screened for variations. Ampliﬁcation comprised 30 cycles
(fragment B1) or 35 cycles (fragment A3) of 3 min at 93C,
8 min at 47C and 4 s at 93C, with a ﬁnal extension step
of 10 min at 47C. The resulting amplicons were separated
by electrophoresis on agarose 0.8% w ⁄v gels and were
visualised under UV light following ethidium bromide
staining. The products were also analysed after restriction
digestion using EcoRI (for PCR fragment A3) or AccI and
HincII (for PCR fragment B1). The toxinotype was then
determined according to the combination of restriction
patterns in PCR fragments A1 and B3 [26,27] (http://
www.mf.uni-mb.si/mikro/tox/). Isolates with toxin genes
similar to the reference strain VPI 10463 were assigned to
toxinotype 0, while isolates with changes in toxin genes
were grouped in toxinotypes I–XXIV. Isolates belonging to
PCR ribotype 027 (see below) were also investigated for
deletions in tcdC using primers Tim2 and Struppi2, as
described by Spigaglia and Mastrantonio [28]. The TcdC
protein is thought to act as a negative regulator of toxin
production.
PCR ribotyping
PCR ribotyping is based on a comparison of patterns of PCR
products from the 16S)23S rRNA intergenic spacer region.
Speciﬁc primers complementary to the 3¢ end of the 16S
rRNA gene and the 5¢ end of the 23S rRNA gene were used
to amplify the variable length intergenic spacer region, as
described previously [29]. PCRs were performed in a ﬁnal
volume of 100 lL containing 2.5 mM MgCl2, 200 lM each
dNTP, 5 pmol of each primer, 2 U of Taq polymerase and
10 lL of template DNA. Ampliﬁcation comprised 35 cycles of
94C for 1 min, 35C for 1 min and 75C for 2 min. PCR
products were analysed on Metaphor agarose (FMC Bio-
products, Rockland, ME, USA) 3% w ⁄v gels and visualised
under UV light after staining the gel for 20 min with
ethidium bromide. PCR ribotype proﬁles were analysed
using GelCompar v.4.0 (Applied Maths, Sint-Martins-Latem,
Belgium).
RESULTS
Analysis of isolates
In total, 411 C. difﬁcile isolates from suspected
cases of CDAD were collected and characterised.
Of the 411 isolates, 354 (86.1%) were toxigenic:
332 were positive for both toxins A and B, and 22
were toxin A-negative toxin B-positive (A–B+).
Among the toxigenic isolates, 268 (75.7%) were
toxinotype 0 and 86 (24.3%) were toxin-variant.
Toxin-variant isolates comprised toxinotypes I
(n = 1), III (n = 25), IV (n = 6), V (n = 28), VI
(n = 2), VIII (n = 22), IX (n = 1), and XXIV (n = 1).
All A–B+ isolates belonged to toxinotype VIII.
MICs of metronidazole, vancomycin, tetracy-
cline, erythromycin, clindamycin and moxiﬂoxa-
cin for 349 of the toxigenic isolates of C. difﬁcile
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are summarised in Table 1. All C. difﬁcile strains
were inhibited by vancomycin £2 mg ⁄L and had
MIC values distributed over a narrow range. The
metronidazole MIC was <0.50 mg ⁄L for all the
isolates. Overall, rates of resistance to erythromy-
cin, clindamycin, tetracycline and moxiﬂoxacin
were 44.4%, 46.1%, 9.2% and 37.5%, respectively,
but the ﬁgures varied widely from one country to
another (Table 2). Overall, co-resistance to eryth-
romycin and moxiﬂoxacin was found in 36.4% of
C. difﬁcile isolates, but reached 100% in isolates of
toxinotype VIII. Resistance to moxiﬂoxacin was
associated signiﬁcantly with resistance to eryth-
romycin; 81.9% of erythromycin-resistant isolates
were concurrently resistant to moxiﬂoxacin,
whereas only 2.1% of erythromycin-susceptible
isolates were resistant to moxiﬂoxacin (p <0.0001).
Resistance to moxiﬂoxacin was more frequent in
isolates from patients who had been treated
previously with ﬂuoroquinolones, compared with
isolates from patients who had not received
ﬂuoroquinolones in the previous month (58.7%
vs. 31.8%, p <0.0001). No signiﬁcant association
was found between resistance to erythromycin
or clindamycin and previous administration of
macrolides.
Only 322 toxigenic strains of C. difﬁcile were
available for PCR ribotyping. The distribution of
the different PCR ribotypes is summarised in
Fig. 1. Sixty-six different PCR ribotypes were
identiﬁed, with 12 PCR ribotypes (001, 002, 012,
014, 017, 020, 027, 048, 077, 078, 126 and 168)
accounting for 65.5% of the isolates. The distribu-
tion of PCR ribotypes varied from one country to
another (Table 2). The phenotypic and genotypic
characteristics of the six major PCR ribotypes (001,
002, 014, 017, 020, 027) are summarised in Table 3.
Table 1. MICs of antimicrobial agents for toxigenic strains
of Clostridium difﬁcile (n = 349)
Antimicrobial
agent
MIC (mg ⁄L)
Range
Geometric
mean MIC50 MIC90
Vancomycin 0.25–2 0.55 0.50 0.75
Metronidazole 0.023–0.50 0.087 0.064 0.125
Erythromycin 0.047-‡256 101.3 1 256
Clindamycin 0.016-‡256 78.8 3 256
Tetracycline 0.023-‡32 2.06 0.032 6
Moxiﬂoxacin 0.032-‡32 8.34 0.5 32
Table 2. Rates of antimicrobial resistance and distribution of the major PCR ribotypes in each participating country
Country
No. of
isolates
available
for MIC
determination
Erythromycin
(% R;
‡4 mg ⁄mL)
Clindamycin
(% R;
‡4 mg ⁄mL)
Tetracycline
(% R;
‡8 mg ⁄mL)
Moxiﬂoxacin
(% R;
‡4 mg ⁄mL)
Co-resistance
to moxiﬂoxacin
and erythromycin
(%)
No. of
isolates
available
for PCR
ribotyping
No. of
different
PCR
ribotypes
Major
(>10%)
PCR
ribotypes
(%)
Belgium 38 39.5 31.6 5.3 34.2 34.2 35 19 027 (31.4)
France 34 29.4 32.4 8.8 11.8 8.8 33 13 014 (21.2)
126 (15.2)
002 (12.1)
Germany 43 46.5 58.1 9.3 41.9 41.9 42 17 168 (21.4)
001 (11.9)
UK 8 87.5 50 0 87.5 87.5 8 4 077 (37.5)
001 (25)
014 (25)
Greece 18 66.7 55.6 38.9 33.3 33.3 11 8 078 (27.3)
017 (18.2)
Hungary 42 31 40.5 21.4 23.8 23.8 42 18 014 (11.9)
048 (11.9)
077 (11.9)
Ireland 26 65.4 50 7.7 65.4 65.4 22 14 017 (18.2)
156 (18.2)
001 (13.6)
Italy 23 26.1 73.9 8.7 17.4 17.4 19 12 020 (26.3)
002 (10.5)
023 (10.5)
070 (10.5)
The Netherlands 20 50 15 0 45 40 20 9 027 (40)
014 (20)
Poland 15 66.7 73.3 14.3 53.3 53.3 16 8 017 (56.3)
Spain 38 78.9 81.6 0 78.9 76.3 37 4 001 (73)
020 (21.6)
Sweden 22 18.2 13.6 0 13.6 13.6 16 12 017 (18.8)
095 (12.5)
023 (12.5)
Switzerland 14 0 14.3 0 7.1 0 14 8 002 (28.6)
014 (21.4)
Turkey 8 12.5 25 12.5 12.5 12.5 7 6 001 (28.6)
Total 349 44.4 46.1 9.2 37.5 36.4 322 – –
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Twenty isolates had a PCR ribotyping pattern
identical to that of the epidemic strain 027 ⁄NAP1
that was responsible for the recent outbreaks
described in North America. The overall preva-
lence of isolates belonging to the epidemic 027
strain was 6.2%. This strain was obtained from
one hospital in Ireland (n = 1), one hospital in The
Netherlands (n = 8) and two hospitals in Belgium
(n = 11). It was of toxinotype III, carried the
binary toxin genes, and had an 18-bp deletion in
tcdC. All the epidemic 027 isolates were highly
resistant to erythromycin (MIC ‡256 mg ⁄L) and
had moxiﬂoxacin MICs of >12 mg ⁄L, except for
one isolate with a moxiﬂoxacin MIC of 6 mg ⁄L.
MICs of clindamycin ranged from 0.25 to 6 mg ⁄L.
Five other isolates of toxinotype III had a PCR
ribotyping pattern that was different from that of
the 027 epidemic strain. These isolates were from
France (n = 1), Belgium (n = 1), Spain (n = 1) and
Sweden (n = 2), and were inhibited by moxiﬂox-
acin 0.75 mg ⁄L. All but one of these isolates was
susceptible to erythromycin.
The ctdA and cdtB genes for binary toxin were
found in 61 (17.2%) toxigenic isolates. All the
isolates that were positive for the binary toxin
genes were also toxin variants. Toxinotypes I and
VIII were the only toxin variants that were
negative for both cdtA and cdtB.
Description of patients with CDAD
In total, 354 patients (51.3% female) met the
criteria for CDAD (i.e., diarrhoea and isolation of
a toxigenic strain of C. difﬁcile). The clinical
features of these patients are summarised in
Table 4. The patients were hospitalised in
medical (73.2%) or surgical (19.1%) wards or in
intensive care units (7.7%). Testing for C. difﬁcile
was requested speciﬁcally by physicians in 296
cases (88.9%), and was performed solely on the
initiative of the laboratory in 37 (11.1%) cases.
The incidence of CDAD could only be calcu-
lated in 23 hospitals for which the number of
hospitalisation-days was available. The mean
Table 3. Phenotypic and genotypic characteristics of the six major PCR ribotypes
PCR
ribotype
No. of
isolates
Erythromycin
(% R; ‡4 mg ⁄mL)
Clindamycin
(% R; ‡4 mg ⁄mL)
Tetracycline
(% R; ‡8 mg ⁄mL)
Moxiﬂoxacin
(% R; ‡4 mg ⁄mL)
Co-resistance to
moxiﬂoxacin and
erythromycin
(%)
Presence of cdtA
and cdtB
(%)
Toxinotype
(%)
001 41 82.9 85.4 0 82.9 82.9 0 0 (97.6)
I (2.4)
002 19 10.5 52.6 0 0 0 0 0 (100)
014 31 3.4 27.6 3.4 6.9 3.4 3.2 0 (96.8)
IV (3.2)
017 19 100 100 27.8 100 100 0 VIII (100)
020 19 26.3 52.6 0 15.8 10.5 0 0 (100)
027 20 100 20a 0 100 100 100 III (100)
aMICs of clindamycin were <8 mg ⁄L for all the isolates.
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Fig. 1. Distribution of PCR
ribotypes among toxigenic strains
of Clostridium difﬁcile (n = 322).
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incidence of CDAD was 2.45 ⁄ 10 000 patient-
days, but ranged from 0.13 to 7.1 ⁄ 10 000
patient-days. The incidence varied widely among
countries, and also among hospitals in the same
country.
CDAD was the primary reason for admission
for 64 (18.8%) patients. The mortality rate within
the month following the diagnosis was 13.4%.
C. difﬁcile infection was considered to be the
primary cause or contributory cause of death for
ﬁve patients, but follow-up was available for only
313 patients. Of the 43 (12.2%) patients who
underwent an endoscopic examination, 14 (4.0%)
had pseudomembranes.
Antibiotics were administered within the
month preceding the onset of diarrhoea to
77.6% of patients (Table 4), with a median of
two antibiotics per patient. Overall, 73.7% of
cases of CDAD were treated speciﬁcally with oral
metronidazole (n = 239, 92.6%) and ⁄ or vancomy-
cin (n = 59, 23.0%).
When patients with CDAD caused by a
binary toxin-positive isolate were compared
with those with binary toxin-negative isolates,
there was no difference with respect to age,
gender, PNN counts, albuminaemia and previ-
ous antimicrobial treatment; however, binary
toxin-positive isolates were associated signiﬁ-
cantly with a more severe form of CDAD
(OR 1.85, 95% CI 0.93–3.66, p 0.05) (Table 5).
Patients with the 027 strain also had a more
severe form of CDAD (p 0.008), had a higher
PNN count (p 0.01), and were treated more
often with vancomycin or metronidazole
(p 0.02). In addition, patients with the 027 strain
Table 4. Clinical features of patients with Clostridium
difﬁcile-associated diarrhoea (CDAD)a
Age (years) (n = 348)
Mean ± SD (median) 65.0 ± 20.6 (70)
Gender (n, %) (n = 343)
Male 167 (48.7%)
PNN count ( ⁄mm3) (n = 294)
‡20 000 ⁄mm3 32 (10.9%)
Albuminaemia (g ⁄L) (n = 181)
Mean ± SD (median) 29.1 ± 7.7 (29)
Community-acquired CDAD (n, %) (n = 345) 71 (20.6%)
Severe CDAD (n, %) (n = 300)b 72 (24.0%)
Endoscopy (n, %) (n = 353) 43 (12.2%)
Pseudomembranous colitis (n, %) (n = 354) 14 (4.0%)
Type of CDAD (n, %) (n = 290)
First episode 243 (83.8%)
Recurrence 47 (16.2%)
Risk-factors in the previous month (n, %)
Previous antibiotic treatment (n = 353) 274 (77.6%)
Previous hospitalisation (n = 327) 156 (47.7%)
Chemotherapy (n = 338) 55 (16.3%)
Nasogastric tube (n = 330) 62 (18.8%)
Selective digestive decontamination (n = 304) 24 (7.9%)
Abdominal surgery (n = 336) 46 (13.7%)
CD4+ counts <200 ⁄mm3 (n = 325) 4 (1.2%)
Previous antimicrobial treatment (n, %) (n = 274)
Penicillins (including aminopenicillins) 109 (39.8%)
Cephalosporins 105 (38.3%)
Penems 36 (13.1%)
Fluoroquinolones 75 (27.4%)
Aminoglycosides 19 (6.9%)
Macrolides 32 (11.7%)
Metronidazole 21 (7.7%)
Glycopeptides 32 (11.7%)
Others 14 (5.1%)
SD, standard deviation; PNN, polynuclear neutrophil.
aTotal number of patients with CDAD was 354; number of patients for whom data
was available is shown in parentheses for each entry.
bCDAD was classiﬁed as severe if the patient fulﬁlled at least one of the following
three criteria: (i) PNN count ‡20 000 ⁄mm3; (ii) death with C. difﬁcile as the primary
or contributory cause, toxic megacolon or perforation; or (iii) colectomy performed
for surgical management of CDAD.
Table 5. Comparison of patients infected with 027 and non-027 strains of Clostridium difﬁcile
Variable
027 strains
(n = 20)
Non-027 strains
(n = 302)
OR
(95% CI) p
Age, years 72.9 + 15.5 (73.5) 64.5 + 20.9 (70) – 0.07
Gender
Male 12 (60%) 140 (47.8%) 1.64 0.29
Female 8 (40%) 153 (52.2%) (0.60–4.58)
Severe CDAD
Yes 10 (50%) 58 (23.3%) 3.29 0.008
No 10 (50%) 191 (76.7%) (1.19–9.16)
PNN count ⁄mm3
‡20 000 6 (30.0%) 23 (9.5%) 4.10 0.001
<20 000 14 (70.0%) 220 (90.5%) (1.25–13.05)
Albuminaemia (g ⁄L)
Mean ± SD
(median)
28.5 ± 5.3
(27)
28.9 ± 7.4
(30)
– 0.84
Community CDAD
Yes 1 (5.3%) 68 (23.1%) 0.18 0.08a
No 18 (94.7%) 226 (76.9%) (0.01–1.36)
Endoscopy
Yes 2 (10%) 36 (12.0%) 0.82 1.00a
No 18 (90%) 265 (88.0%) (0.12–3.95)
Speciﬁc treatment
Yes 19 (95%) 214 (71.8%) 7.46 0.02a
No 1 (5%) 84 (28.2%) (1.02–154)
PNN, polynuclear neutrophil; CDAD, Clostridium difﬁcile-associated diarhoea.
aFisher’s exact test.
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had CDAD that was healthcare-associated more
often than did patients infected with another
toxigenic strain, although this difference did not
reach statistical signiﬁcance.
DISCUSSION
Epidemiological studies concerning C. difﬁcile are
often limited to surveys at a hospital or country
level. The present study is the ﬁrst European-
wide survey of C. difﬁcile isolates from patients
suspected of having CDAD. Although the results
at the country level must be interpreted with
caution, because the small number of participat-
ing hospitals within a country might not be
representative of the entire country, the data
available from 38 hospitals in 14 different coun-
tries indicated a higher incidence of CDAD in
countries that had experienced recent outbreaks
with 027 strains, i.e., The Netherlands, Belgium
and France, than in countries where 027 strains
have not been reported to date, i.e., Italy, Turkey
and Greece. Other factors that could explain
differences in the incidence of CDAD include the
awareness of physicians of C. difﬁcile-associated
infections, as well as strategies and methods
used in laboratories for C. difﬁcile testing [30].
Although the deﬁnition used for CDAD, based
on toxigenic culture, probably overestimated the
number of cases by detecting carriers of toxi-
genic strains, the mean incidence
(2.45 ⁄ 10 000 patient-days) remains much lower
than that in the USA and Canada, where
incidence rates range from 4 to >25 ⁄ 10 000
admissions [15,17,31,32]. To facilitate benchmark-
ing and comparison of rates of CDAD among
institutions, a more standardised case deﬁnition
and strategy for C. difﬁcile testing should be
implemented, as suggested by a recent European
working group on C. difﬁcile [33].
The present ﬁndings indicate an increased
proportion of toxin-variant strains (24.3%) com-
pared with that reported from the USA (12%),
England (7.7%) and France (6%) [11,12,14,25].
Toxinotypes III, VIII and V were the most fre-
quent toxin-variant strains [11,12,14,25], and no
new toxinotypes were identiﬁed. The high pro-
portion of toxin-variant isolates also accounts for
the high proportion of binary toxin-positive iso-
lates.
The overall distribution of PCR ribotypes
revealed a large diversity of strains throughout
Europe. Nevertheless, the distribution of PCR
ribotypes varied from one hospital and ⁄ or coun-
try to another. For example, in three hospitals in
the Madrid area of Spain, PCR ribotype 001
accounted for 73% of the isolates, suggesting
local spread of this clone. In contrast, PCR
ribotype 017 was particularly predominant in
hospitals in Poland and Ireland, where it ac-
counted for up to 80% of toxigenic isolates within
a hospital. This result agrees with previous data
reporting outbreaks associated with this PCR
ribotype in these countries [34]. All PCR ribotype
017 isolates belonged to toxinotype VIII and were
A–B+. These isolates would therefore not be
detected by enzyme immunoassays that detect
only toxin A. The increasing frequency of A–B+
isolates means that enzyme immunoassays
capable of detecting both toxins A and B should
now be used routinely in diagnostic laboratories
[35].
The overall prevalence of the epidemic 027
strain in 2005 was 6.2%, but this ﬁgure reached
40% and 31.4% in The Netherlands and Belgium,
respectively. This strain was not isolated in the
UK, where it has been shown previously to be
endemic; however, only one hospital from the UK
participated in the survey. Recent reports indicate
that this strain may disseminate very rapidly
[22,23,36]. In Quebec, a retrospective analysis of a
collection of 178 isolates showed that 75.2% were
C. difﬁcile 027, and this strain has also been found
in western Canada, where it represents 5.9% of
isolates [20]. The same trends have been observed
in The Netherlands, Belgium and the UK, where
the 027 strain became the major PCR ribotype
found among isolates referred to the National
Reference Laboratories for C. difﬁcile [36,37].
These data suggest that the 027 strain might be
more transmissible or virulent than other strains,
and ⁄ or that it might be selected by environmental
or antibiotic pressure. Periodic characterisation of
C. difﬁcile isolates is therefore required to monitor
the spread of the 027 strain in European countries,
and to detect and control the emergence of new
epidemic strains in a timely manner. Culturing of
C. difﬁcile from patients positive for toxins,
although not performed routinely in most coun-
tries, is highly recommended [30].
The European PCR ribotype 027 strain has the
same phenotypic and genotypic features as the
NAP1 (North American Pulsotype) strain, sug-
gesting that international spread has occurred
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[15,16,38]. This strain is positive for the binary
toxin gene, and has an 18-bp deletion in the tcdC
gene and a frameshift in position 117 that is
implicated in down-regulation of the tcdA and
tcdB genes. Moreover, this strain is resistant to
both erythromycin and moxiﬂoxacin, but has a
clindamycin MIC of <8 mg ⁄L. This MIC value
represents the breakpoint established recently by
the CLSI [39], according to which the four 027
isolates that were found to be resistant to clinda-
mycin would be considered as intermediate. Co-
resistance to moxiﬂoxacin and erythromycin is
not speciﬁc for 027 isolates, since 34.7% of non-
027 isolates were also resistant to both antibiotics.
Antimicrobial susceptibility testing of isolates
might be used as a simple method to screen for
the 027 strain, but only isolates resistant to both
moxiﬂoxacin and erythromycin should then be
conﬁrmed as the 027 strain by PCR ribotyping. A
single transition mutation (C to T) in gyrA,
resulting in the amino-acid substitution
Thr82 ﬁ Ile, has been described for ﬁve 027
isolates, resistant to ﬂuoroquinolones, isolated
during an outbreak in Ireland [40].
Using univariate analysis, patients infected by
the 027 strain were shown to be more likely to
have a severe form of CDAD and to have been
treated speciﬁcally with metronidazole or vanco-
mycin, thereby suggesting enhanced virulence of
the 027 strain. Multivariate analysis could not be
performed because of the low number of cases of
CDAD caused by these isolates. Several previous
studies have reported higher rates of mortality
and degrees of severity in patients with CDAD in
the context of outbreaks associated with 027
isolates, but few have addressed the direct rela-
tionship between 027 isolates and the severity of
disease. Loo et al. [15] reported that severe CDAD
was observed more often in patients infected with
an 027 strain, as compared with other strains, but
that the difference was not statistically signiﬁcant
(15.5% vs. 7.1%, p 0.34) [15]. The virulence of the
027 strain is thought to be mediated by over-pro-
duction of toxins A and B (16- and 23-fold higher,
respectively, than control strains of toxinotype 0)
and ⁄ or by the presence of binary toxin [19]. The
precise role of binary toxin in the virulence of
C. difﬁcile remains controversial. Two epidemio-
logical studies have suggested that binary toxin is
associated signiﬁcantly with more severe clinical
disease and a higher case fatality rate [41,42].
Nevertheless, contradictory results have been
obtained using the hamster cecitis model and
the rabbit ileal loop model [43].
The present survey also aimed to obtain an
overview of the antibiotic susceptibilities of C. dif-
ﬁcile isolates in Europe during 2005. All C. difﬁcile
isolates were fully-susceptible to metronidazole
and vancomycin, the two major antibiotics used
for the treatment of CDAD. Consequently, met-
ronidazole and vancomycin still seem to be
appropriate agents for empirical treatment of
CDAD, although poorer outcomes and increasing
rates of relapse with metronidazole have been
reported [44,45]. The threat of emergence and
dissemination of resistance to these antibiotics
should prompt periodic monitoring of the in-vitro
susceptibility patterns of C. difﬁcile, using stan-
dardised and validated methods.
Resistance to moxiﬂoxacin (37.5%) seems to
have increased dramatically recently, compared
with the rate of 7% reported in France in 1991 and
1997, and the rate of 12% reported in Germany
between 1986 and 2001 [46,47]. The differences in
resistance rates observed in each country might
be explained by the local spread of speciﬁc PCR
ribotypes (i.e., 001, 017 or 027) that are character-
ised by resistance to ﬂuoroquinolones. Interest-
ingly, resistance to moxiﬂoxacin was found to be
associated signiﬁcantly with preceding use of
ﬂuoroquinolones, as suggested previously [48].
Fluoroquinolone administration also emerged as
the most important risk-factor for CDAD in
Quebec during the epidemic caused by the 027
strain [49]. It can be hypothesised that the anti-
biotic pressure exerted by new ﬂuoroquinolones
that exhibit an anti-anaerobic activity on colonic
ﬂora may have promoted the emergence and
dissemination of the 027 strain. Active surveil-
lance for the 027 strain should be implemented in
countries with a high level of ﬂuoroquinolone
consumption.
In conclusion, this epidemiological study re-
vealed that the incidence of CDAD is highly
variable among European countries, but
remained low during 2005. However, the epi-
demic 027 strain responsible for recent outbreaks
of infection in the USA and Canada has already
spread to at least three European countries. This
strain has the same microbiological features as the
NAP1 strain described in North America. The 027
strain was associated with a more severe form of
CDAD, suggesting that this clone may be more
virulent. Continuous epidemiological surveillance
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of CDAD and periodic microbiological charac-
terisation of C. difﬁcile isolates are required to
detect clustering of cases in time or space, and to
monitor and control the emergence of speciﬁc
clones in a timely manner.
ACKNOWLEDGEMENTS
This study was supported by grants from the European Society
of Clinical Microbiology and Infectious Diseases (ESCMID),
the European Union (No. 037870 ⁄EACCAD) and from Bioco-
dex and Genzyme laboratories. We are indebted to the
following microbiologists who were involved in providing
clinical data and isolates: C. Nonhoff, M. Struelens, J. Verhae-
gen, J. L. Pons, F. Mory, V. Lalande, E. Urban, M. G. Menozzi,
M. L. D’annibale, P. Nicoletti, R. Dei, E. Papafrangas, M.
Kanellopoulou, A. Avlami, G. Nurzynska, D. Wultanska, M.
Sanchez-Somolinos, M. Concheiro, J. Rodriguez-Sontanos, L.
Alcala, M. Mamal Torun, S. Ercis, G. Soyletir, N. Ulger, C.
Hohne, M. Kist, O. Hasselmayer, C. Visser, M. F. Peeters, R.
van den Berg, N. Harnedy, S. Fitzgerald and A. P. Gibb. We are
also indebted to M. R. Popoff for providing strain CD196, to B.
Dupuy for providing the epidemic strain PCR ribotype
027 ⁄NAP1, to P. Spigaglia and F. Barbanti for performing the
antibiotic susceptibility assays, to J. Van Broeck for performing
toxin detection, to C. Harmanus for performing PCR ribotyp-
ing, and to B. Burghoffer for performing toxinotyping and
binary toxin detection. We are also very grateful to AB Biodisk
(Solna, Sweden) for generously providing the Etest strips and
to Oxoid (Belgium) for providing some of the ToxA kits.
REFERENCES
1. Bartlett JG, Moon N, Chang TW, Taylor N, Onderdonk AB.
Role of Clostridium difﬁcile in antibiotic-associated pseudo-
membranous colitis. Gastroenterology 1978; 75: 778–782.
2. Larson HE, Price AB, Honour P, Borriello SP. Clostridium
difﬁcile and the aetiology of pseudomembranous colitis.
Lancet 1978; i: 1063–1066.
3. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difﬁcile
colitis. N Engl J Med 1994; 330: 257–262.
4. McFarland LV, Mulligan ME, Kwok RY, Stamm WE.
Nosocomial acquisition of Clostridium difﬁcile infection. N
Engl J Med 1989; 320: 204–210.
5. Barbut F, Mario N, Meyohas MC, Binet D, Frottier J, Petit
JC. Investigation of a nosocomial outbreak of Clostridium
difﬁcile-associated diarrhoea among AIDS patients by
random ampliﬁed polymorphic DNA (RAPD) assay.
J Hosp Infect 1994; 26: 181–189.
6. Cartmill TD, Panigrahi H, Worsley MA, McCann DC, Nice
CN, Keith E. Management and control of a large outbreak
of diarrhoea due to Clostridium difﬁcile. J Hosp Infect 1994;
27: 1–15.
7. Muto CA, Pokrywka M, Shutt K et al. A large outbreak of
Clostridium difﬁcile-associated disease with an unexpected
proportion of deaths and colectomies at a teaching hos-
pital following increased ﬂuoroquinolone use. Infect Con-
trol Hosp Epidemiol 2005; 26: 273–280.
8. Voth DE, Ballard JD. Clostridium difﬁcile toxins: mechanism
of action and role in disease. Clin Microbiol Rev 2005; 18:
247–263.
9. Popoff MR, Rubin EJ, Gill DM, Boquet P. Actin-speciﬁc
ADP-ribosyltransferase produced by a Clostridium difﬁcile
strain. Infect Immun 1988; 56: 2299–2306.
10. Perelle S, Gibert M, Bourlioux P, Corthier G, Popoff MR.
Production of a complete binary toxin (actin-speciﬁc ADP-
ribosyltransferase) by Clostridium difﬁcile CD196. Infect
Immun 1997; 65: 1402–1407.
11. Geric B, Rupnik M, Gerding DN, Grabnar M, Johnson S.
Distribution of Clostridium difﬁcile variant toxinotypes and
strains with binary toxin genes among clinical isolates in
an American hospital. J Med Microbiol 2004; 53: 887–894.
12. Goncalves C, Decre D, Barbut F, Burghoffer B, Petit JC.
Prevalence and characterization of a binary toxin (actin-
speciﬁc ADP-ribosyltransferase) from Clostridium difﬁcile.
J Clin Microbiol 2004; 42: 1933–1939.
13. Pituch H, Rupnik M, Obuch-Woszczatynski P, Grubesic A,
Meisel-Mikolajczyk F, Luczak M. Detection of binary-toxin
genes (cdtA and cdtB) among Clostridium difﬁcile strains
isolated from patients with C. difﬁcile-associated diarrhoea
(CDAD) in Poland. J Med Microbiol 2005; 54: 143–147.
14. Rupnik M, Kato N, Grabnar M, Kato H. New types of
toxin A-negative, toxin B-positive strains among Clostrid-
ium difﬁcile isolates from Asia. J Clin Microbiol 2003; 41:
1118–1125.
15. Loo VG, Poirier L, Miller MA et al.A predominantly clonal
multi-institutional outbreak of Clostridium difﬁcile-associ-
ated diarrhea with high morbidity and mortality. N Engl J
Med 2005; 353: 2442–2449.
16. McDonald LC, Killgore GE, Thompson A et al. An
epidemic, toxin gene-variant strain of Clostridium difﬁcile.
N Engl J Med 2005; 353: 2433–2441.
17. Pepin J, Valiquette L, Alary ME et al. Clostridium difﬁcile-
associated diarrhea in a region of Quebec from 1991 to
2003: a changing pattern of disease severity. Can Med Assoc
J 1991; 171: 466–472.
18. Pepin J, Valiquette L, Cossette B. Mortality attributable to
nosocomial Clostridium difﬁcile-associated disease during
an epidemic caused by a hypervirulent strain in Quebec.
Can Med Assoc J 2005; 173: 1037–1042.
19. Warny M, Pepin J, Fang A et al. Toxin production by an
emerging strain of Clostridium difﬁcile associated with
outbreaks of severe disease in north America and Europe.
Lancet 2005; 366: 1079–1084.
20. MacCannell DR, Louie TJ, Gregson DB et al. Molecular
analysis of Clostridium difﬁcile PCR ribotype 027 isolates
from eastern and western Canada. J Clin Microbiol 2006; 44:
2147–2152.
21. Joseph R, Demeyer D, Vanrenterghem D, van den Berg R,
Kuijper E, Delme´e M. First isolation of Clostridium difﬁcile
PCR ribotype 027, toxinotype III in Belgium. Euro Surveill
2005; 10: E051020–E051024.
22. Kuijper EJ, Van den Berg RJ, Debast S et al. Clostridium
difﬁcile ribotype 027, toxinotype III, the Netherlands. Emerg
Infect Dis, 2006; 12: 827–830.
23. Tachon M, Cattoen C, Blanckaert K et al. First cluster of C.
difﬁcile toxinotype III, PCR-ribotype 027 associated disease
in France: preliminary report. Euro Surveill 2006; 11:
E060504.1.
24. Delme´e M, Thonnard J. Clostridium difﬁcile toxin A
detection on colonies. Clin Microbiol Infect 1997; 3: 389–
390.
25. Stubbs S, Rupnik M, Gibert M, Brazier J, Duerden B,
Popoff M. Production of actin-speciﬁc ADP-ribosyltrans-
1056 Clinical Microbiology and Infection, Volume 13 Number 11, November 2007
 2007 The Authors
Journal Compilation  2007 European Society of Clinical Microbiology and Infectious Diseases, CMI, 13, 1048–1057
ferase (binary toxin) by strains of Clostridium difﬁcile.
FEMS Microbiol Lett 2000; 186: 307–312.
26. Rupnik M, Avesani V, Janc M, von Eichel-Streiber C,
Delme´e M. A novel toxinotyping scheme and correlation
of toxinotypes with serogroups of Clostridium difﬁcile iso-
lates. J Clin Microbiol 1998; 36: 2240–2247.
27. Rupnik M. How to detect Clostridium difﬁcile variant
strains in a routine laboratory. Clin Microbiol Infect 2001; 7:
417–420.
28. Spigaglia P, Mastrantonio P. Molecular analysis of the
pathogenicity locus and polymorphism in the putative
negative regulator of toxin production (tcdC) among
Clostridium difﬁcile clinical isolates. J Clin Microbiol 2002; 40:
3470–3475.
29. Stubbs SL, Brazier JS, O’Neill GL, Duerden BI. PCR tar-
geted to the 16S)23S rRNA gene intergenic spacer region
of Clostridium difﬁcile and construction of a library con-
sisting of 116 different PCR ribotypes. J Clin Microbiol 1999;
37: 461–463.
30. Barbut F, Delme´e M, Brazier JS et al. A European survey of
diagnostic methods and testing protocols for Clostridium
difﬁcile. Clin Microbiol Infect 2003; 9: 989–996.
31. Sohn S, Climo M, Diekema D et al. Varying rates of Clos-
tridium difﬁcile-associated diarrhea at prevention epicenter
hospitals. Infect Control Hosp Epidemiol 2005; 26: 676–679.
32. Archibald LK, Banerjee SN, Jarvis WR. Secular trends in
hospital-acquired Clostridium difﬁcile disease in the United
States, 1987–2001. J Infect Dis 2004; 189: 1585–1589.
33. Kuijper EJ, Coignard B, Tull P. Emergence of Clostridium
difﬁcile-associated disease in North America and Europe.
Clin Microbiol Infect 2006; 12 (suppl 6): 2–18.
34. Pituch H, van LeeuwenW, Maquelin K et al. Toxin proﬁles
and resistances to macrolides and newer ﬂuoroquinolones
as epidemicity determinants of clinical isolates of Clos-
tridium difﬁcile from Warsaw, Poland. J Clin Microbiol 2007;
45: 1607–1610.
35. National Clostridium difﬁcile Standards Group. Report to
the Department of Health. J Hosp Infect 2004; 56 (suppl 1):
1–38.
36. Delme´e M, Ramboer I, Van Broeck J, Suetens C. Epide-
miology of Clostridium difﬁcile toxinotype III, PCR-ribotype
027 associated disease in Belgium, 2006. Euro Surveill 2006;
11: E060914.2.
37. Coignard B, Barbut F, Blanckaert K et al. Emergence of
Clostridium difﬁcile toxinotype III, PCR-ribotype 027-asso-
ciated disease, France, 2006. Euro Surveill 2006; 11:
E060914.1.
38. Bourgault AM, Lamothe F, Loo VG, Poirier L. In vitro
susceptibility of Clostridium difﬁcile clinical isolates from a
multi-institutional outbreak in Southern Quebec, Canada.
Antimicrob Agents Chemother 2006; 50: 3473–3475.
39. Clinical and Laboratory Standards Institute. Methods for
antimicrobial susceptibility testing of anaerobic bacteria, 7th
edn. Wayne, PA: CLSI, 2007.
40. Drudy D, Kyne L, O’Mahony D, Fanning S. GyrA muta-
tions in ﬂuoroquinolone-resistant Clostridium difﬁcile PCR-
027. Emerg Infect Dis 2007; 13: 504–505.
41. Barbut F, Decre´ D, Lalande V et al. Clinical features of
Clostridium difﬁcile-associated diarrhoea due to binary
toxin (actin-speciﬁc ADP-ribosyltransferase)-producing
strains. J Med Microbiol 2005; 54: 181–185.
42. Barbut F, Gariazzo B, Bonne L et al. Clinical features of
Clostridium difﬁcile-associated infections and molecular
characterization of strains: results of a retrospective
study, 2000–2004. Infect Control Hosp Epidemiol 2007; 28:
131–139.
43. Geric B, Carman RJ, Rupnik M et al. Binary toxin-pro-
ducing, large clostridial toxin-negative Clostridium difﬁcile
strains are enterotoxic but do not cause disease in ham-
sters. J Infect Dis 2006; 193: 1143–1150.
44. Musher DM, Aslam S, Logan N et al. Relatively poor
outcome after treatment of Clostridium difﬁcile colitis with
metronidazole. Clin Infect Dis 2005; 40: 1586–1590.
45. Pepin J, Alary ME, Valiquette L et al. Increasing risk of
relapse after treatment of Clostridium difﬁcile colitis in
Quebec, Canada. Clin Infect Dis 2005; 40: 1591–1597.
46. Ackermann G, Degner A, Cohen SH, Silva J, Rodloff AC.
Prevalence and association of macrolide–lincosamide–
streptogramin B (MLS(b)) resistance with resistance to
moxiﬂoxacin in Clostridium difﬁcile. J Antimicrob Chemother
2003; 51: 599–603.
47. Dridi L, Tankovic J, Burghoffer B, Barbut F, Petit JC. gyrA
and gyrB mutations are implicated in cross-resistance to
ciproﬂoxacin and moxiﬂoxacin in Clostridium difﬁcile.
Antimicrob Agents Chemother 2002; 46: 3418–3421.
48. Ackermann G, Tang-Feldman YJ, Schaumann R et al.
Antecedent use of ﬂuoroquinolones is associated with
resistance to moxiﬂoxacin in Clostridium difﬁcile. Clin
Microbiol Infect 2003; 9: 526–530.
49. Pepin J, Saheb N, Coulombe MA et al. Emergence of
ﬂuoroquinolones as the predominant risk factor for
Clostridium difﬁcile-associated diarrhea: a cohort study
during an epidemic in Quebec. Clin Infect Dis 2005; 41:
1254–1260.
Barbut et al. Characterisation of C. difﬁcile in Europe 1057
 2007 The Authors
Journal Compilation  2007 European Society of Clinical Microbiology and Infectious Diseases, CMI, 13, 1048–1057
